Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.61 |
| ▸ | TOP1 | P11387 | 3/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28018828 | 0.85 | TGFBR1 (0.48) | TGFBR1 | |
| SCHEMBL15639583 | 0.81 | TGFBR1 (0.51) | TGFBR1TOP1PIK3CA | |
| SCHEMBL15640132 | 0.81 | TGFBR1 (0.57) | TGFBR1TOP1MAPK14 | |
| SCHEMBL15639821 | 0.78 | TGFBR1 (0.47) | TGFBR1TOP1PIK3CAPDE10A | |
| SCHEMBL30117887 | 0.77 | PTGS2 (0.51) | TGFBR1TOP1MAPK14MAPK10CSNK1D | |
| SCHEMBL15638432 | 0.77 | PTGS2 (0.51) | TGFBR1TOP1MAPK14MAPK10CSNK1D | |
| SCHEMBL6581932 | 0.77 | MAPK14 (0.51) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL15640150 | 0.76 | BCHE (0.49) | TGFBR1PDE10A | |
| SCHEMBL15639907 | 0.76 | TGFBR1 (0.48) | TGFBR1TOP1MAPK14PDE10A | |
| Gw785804X SCHEMBL373499 | 0.76 | TGFBR1 (1.00) | TGFBR1TOP1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | TGFBR1 3/4885TOP1 874/4885MAPK14 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.